Recalcitrant Issues and New Frontiers in Nano-Pharmacology
- 1The College of New Jersey, United States
- 2Florida International University, United States
- 3Nicklaus Children's Health System, United States
Packaging of old pharma drugs into new packaging “nanoparticles” is called nano-pharmacology and the products are called nano-based drugs. The inception of nano-pharmacology research and development (R&D) is marked by the approval of the first nano-based drug Doxil® in 1995 by the Food and Drug Administration. However, even after more than two decades, today, there are only ~20 nano-based drugs in the market to treat cancers and brain diseases. In this article we share the perspectives of nanotechnology scientists, engineers and clinicians on the roadblocks in nano-pharmacology R&D. Also, we share our opinion on new frontiers in the field of nano-pharmacology R&D that may allow rapid and efficient transfer of nano-pharma technologies from R&D to market.
Keywords: Theranostics (combined therapeutic and diagnostic technology), Biomedical Imaging, Nanomedicine, brain disease, Cancer, Nanotechnology
Received: 03 Jul 2019;
Accepted: 29 Oct 2019.
Copyright: © 2019 Bhardwaj, Kaushik, Khatib, Nair and McGoron. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
PhD. Vinay Bhardwaj, The College of New Jersey, Ewing Township, United States, firstname.lastname@example.org
PhD. Anthony J. McGoron, Florida International University, Miami, 33199, Florida, United States, email@example.com